Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price target reduced by Oppenheimer from $190.00 to $180.00 in a research note published on Friday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. A number of other research firms have also recently issued reports on ASND. Evercore ISI boosted their price […]